Gelonghui announced on March 11: Sinqi Pharmaceutical (300573.SZ). Today, Shenyang Xingqi Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for atropine sulfate eye drops approved and issued by the State Drug Administration.
The company's development code for atropine sulphate eye drops is SQ-729. This product is an ophthalmic preparation with atropine sulfate as the active ingredient. The approved clinical indication is that this product is used to slow the progression of myopia in children aged 6 to 12 with spherical specular intensity of -1.00D to -4.00D (astigmatism ≤ 1.50D, refractive error ≤ 1.50D). Currently, there are no similar products with myopia-related indications on the market. Similar atropine sulfate eye drops have been sold abroad, including 0.01% atropine sulphate eye drops such as Aspen Australia and Entod India.